Skip to main content

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

MTRC is growing capacity in the health economic field

We are pleased to announce the expansion of our HEOR Department with the addition of Elizaveta Fedina, an experienced health economist with a strong background in health technology assessment (HTA) and economic evaluation.

Elizaveta Fedina holds a Master of Public Health from the University of Melbourne, Australia (2019), specializing in Health Economics and Economic Evaluation, supported by the Global Education Scholarship. Additionally, she has a BSc in Sport and Health Sciences from the University of Exeter, UK (2017).

Her expertise includes HTA for reimbursement decisions, budget impact analyses, cost-effectiveness modeling, and economic evaluations of public health interventions. She has contributed to multiple peer-reviewed publications in esteemed journals such as Value in Health and the Eurasian Heart Journal, focusing on cost-effectiveness studies and meta-analyses of healthcare interventions.

Beyond research and analysis, Elizaveta Fedina has experience in academic tutoring in health economics at the University of Melbourne and has designed training courses for new professionals in the field.

If you are interested in learning more about our health economic analysis and evidence synthesis capabilities, please reach out to us to arrange a call to discuss your needs.